Eczacibasi Ilac stock carries TRY 43.3 billion market value
Published on 09/30/2026 at 10:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eczacibasi Ilac stock carried a market value of TRY 43.3 billion on September 30, 2026, while the company moved ahead with a corporate merger disclosed six days earlier. The transaction combines Eczacibasi Ilac with its wholly owned real estate subsidiary, adding a defined restructuring event to the investment case.
Merger reaches regulatory stage
According to Dunya Gazetesi on September 24, 2026, Eczacibasi Ilac applied to the Capital Markets Board for approval of the simplified merger. The filing states that the company would absorb Eczacibasi Gayrimenkul Gelistirme ve Yatirim, a wholly owned subsidiary, with assets and liabilities transferred at their registered values.
The filing also lists issued capital of TRY 685.26 million and leaves that amount unchanged after the transaction. The structure matters because Eczacibasi Ilac operates as a holding company with exposure to pharmaceuticals, healthcare products, industrial activity and financial investments.
Half year loss remains central
A FVT report covering the first six months of 2026 puts revenue at TRY 5.2 billion and net loss at TRY 1.9 billion. The figures keep operating performance central to the merger story because the corporate change does not itself remove pressure from the income statement.
The company describes its investor-relations platform as covering healthcare, building products, consumer goods, natural resources, technology, finance and real estate activities. Its pharmaceutical and industrial investment arm therefore combines operating exposure with balance-sheet and portfolio decisions, rather than representing a pure drug manufacturer.
Stock remains below yearly high
On Borsa Istanbul, the stock was trading at TRY 63.25 on September 30, 2026 at 11:01 a.m. TRT, down 1.33 percent from TRY 64.10. The same quote shows a 52-week range of TRY 54.80 to TRY 132.60, placing the current level 52.30 percent below the yearly high.
The market snapshot gives the merger a clear numerical backdrop: the company has a TRY 43.3 billion market value, while first-half revenue reached TRY 5.2 billion and the net loss stood at TRY 1.9 billion. For investors, the next assessment point is how the restructuring interacts with the healthcare portfolio and the reported loss profile.
Eczacibasi Ilac stock facts
- Company: EIS Eczacibasi Ilac, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.
- Ticker: ECILC
- Primary exchange: Borsa Istanbul
- Market capitalization: TRY 43.3 billion (as of September 30, 2026)
- 52-week range: TRY 54.80-TRY 132.60 (as of September 30, 2026)
- Sector / Industry: Healthcare and pharmaceuticals
- Index membership: BIST 100
